SERAXIS

Seraxis is a private biotechnology company launched in March 2013. Incorporated in Singapore and the United States, their GMP lab is located in Germantown, Maryland. Seraxis team of scientists developed novel cell and encapsulation technologies. Their main goal is to bring a practical cell therapy for insulin-dependent diabetes to the clinic and provide a long term cure to patients that does not require the use of immuno-suppression. Their corporate structure and strategy is designed to achieve that goal as quickly as possible, while bringing maximum value to their shareholders.